Captrust Financial Advisors Adverum Biotechnologies, Inc. Transaction History

Captrust Financial Advisors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.33 $30,750 - $47,765	20,500 New	20,500 $30,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $1,120 - $1,776	-911 Reduced 64.56%	500 $1,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $657 - $907	378 Added 36.59%	1,411 $2,000
Q3 2021 Nov 16, 2021	BUY	$2.08 - $3.6 $1,108 - $1,918	533 Added 106.6%	1,033 $2,000
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $4,265 - $12,820	500 New	500 $11,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.